Objective To evaluate the prevalence of epilepsy and to assess secular trends in the life-time prevalence of epilepsy in rural China over a 12-year period. Conclusions Life-time prevalence of epilepsy seems to have significantly decreased in rural China over a 12-year period. We hypothesize that it may be attributed to decreased incidence and increased premature mortality.
Introduction
Epilepsy affects up to 70 million people worldwide. 1 More than 80% of the global burden of epilepsy is found in resource-poor settings where the condition is largely untreated. 2 In China, epilepsy prevalence estimates ranged from 0.90‰ to 8 . 50‰
during the 1980s and 2000s. 3 In 2003, it was estimated there were at least 9 million people with epilepsy in China. 3 In the last two decades there has been significant economic growth, rapid urbanization and demographic changes with an increase aging of the population. Epilepsy awareness has also increased. These social changes may have impacted epilepsy prevalence.
Recently, a systematic review 4 using modeling suggested that the life-time epilepsy prevalence in China increased substantially between 1990 and 2015, with prevalence having more than doubled and the number of people with epilepsy more than tripled (with an overall increase in the Chinese population). This is not consistent with the notion that epilepsy is a condition with a generally low prevalence. 5 A recent review focusing on epilepsy in Asia only referenced the few Chinese epidemiological surveys published in English, omitting many more studies reported in Chinese, thus introducing a publication bias. 6 In 2000-2002 and in 2012-2013, we conducted two cross-sectional populationbased surveys to determine the life-time prevalence of epilepsy with identical protocols in the same areas of rural China. It offered us the opportunity to re-examine the prevalence of epilepsy in rural China, and to assess the secular trend in the recent past.
Methods

Study design and participants
We applied a multi-stage random cluster sampling based on Chinese census units (Figure 1 ). Participants were enrolled if they met residency criteria: living in the area regardless of household registration for more than a month. Those with household registration were also enrolled if they had temporarily left the area for less than 1 month at the time of the survey. Lists of residents were extracted from the local population registration system. Guardians or relatives of children younger than 15 years and of people aged over 70 years, as well as those with learning disabilities, were interviewed to obtain accurate data.
Survey procedure
The survey procedure included two stages of screening and ascertaining epilepsy cases in the target population. At the screening stage, well-trained local village physicians and health workers performed door-to-door interviews to enroll participants to complete the screening questionnaire. The questionnaire was based on the WHO screening questionnaires previously used in China and on the International Community-based Epilepsy Research Group (ICBERG) screening instrument with specificity (78.5%) and sensitivity (100%) previously validated in China. 7 In the diagnosis-ascertaining stage, "definitive" or "suspected" epilepsy cases reported from populations in each site in the two surveys did not necessarily overlap but were in adjacent communities. Some datasets from the first survey were previously analyzed and reported, 3 but for this study we obtained the raw data and re-analyzed it.
Operational definitions
Following guidelines for epidemiologic studies, 
Statistical analysis
The minimal sample size for each site was estimated at 2052, using PASS version 11.0 Software and the formula for population surveys. We used an expected prevalence of 2.89‰ provided by a systematic review 10 , a 95% confidence interval (CI) and a 5‰ expected CI Width (two-sided).
The life-time prevalence rate of epilepsy was estimated as the number of people having had epilepsy at any point in their lifetime, divided by the number of participants, and described as "number ‰" with 95%CI. This was estimated for the entire population, and for age group and site. The standardized prevalence was calculated by the direct method using the population age structure reported in the 2012 national population census as the reference population. 11 Chi-squared tests or
Fisher's exact tests were used to explore the differences between the prevalence rates in the two surveys.
The 95% CIs were derived from the Wilson Score tests. 12 P-values and 95% CIs were estimated in a two-tailed fashion. Differences were considered to be statistically significant at p<0.05. All statistical analyses were performed using SPSS 22.0 software for Windows (SPSS Inc., Chicago, IL, USA).
Results
The decreased by 52% (P<0 . 001) ( Table 1) . 
Discussion
We ascertained trends of life-time prevalence of epilepsy over a 12-year period through two epidemiological surveys using identical protocols. The life-time prevalence decreased significantly over the period and this was seen in all sites and most age-specific groups.
There are few longitudinal studies of secular changes of epilepsy prevalence.
Work conducting decennial censuses in Minnesota from 1935 to 1984 showed that the life-time prevalence increased with each subsequent census. 13 A population of about 6000 people in Britain was assessed 10 years apart, and life-time prevalence increased slightly but without statistical significance. 14 In China, two door-to-door surveys conducted in 2000 and 2004 in the same six areas of rural China reported a decrease in life-time prevalence, though not statistically significant. 15 Recently, a systematic review 4 estimated the life-time epilepsy prevalence trends in China using modeling; the life-time prevalence estimations increased by nearly 260% in a 15-year period.
This review has limitations. Firstly, the selected population-based surveys had large variations in study design, screening instruments, diagnostic criteria, and sampling locations, thus rendering the data unsuitable for pooling due to heterogeneity.
Secondly, prevalence rates in 1990, 2000, and 2015 were not similar to contemporaneously reported multi-center population-based studies in China. 3, [16] [17] [18] Thirdly, among total participants, only about 5% specific data points based on age, sex and location provided the information on life-time epilepsy prevalence. These small numbers were used, leading to wide CIs in age groups especially in 2015. This suggests that the large increase in life-time epilepsy prevalence is in doubt.
We searched Pubmed and Chinese Databases for reports in either English or Chinese languages on door-to-door epidemiological surveys involving at least life-time prevalence in China since 2000 and extracted data when available (Table 2 ). In the table, though very few studies were conducted in the same areas, general downward trends in life-time prevalence, active prevalence and incidence can be seen. Active prevalence in the table is defined as a person with epilepsy who has had at least two unprovoked seizures on different days in the previous year, regardless of antiepileptic drug (AED) treatment. Common-1: The diagnosis of epilepsy: 1) the condition must be characterized by two or more unprovoked epileptic seizures; 2) individuals with febrile seizures were excluded. Common-2: The diagnosis of epilepsy: 1) the condition must be characterized by two or more unprovoked epileptic seizures; 2) individuals with febrile seizures or seizures related to certain acute cerebral disorders or acute metabolic disorders or to withdrawal of alcohol or drugs were excluded. Without recorded mass in-and out-migration or major demographic alteration in the population structure, life-time prevalence is determined by the rate at which new cases arise and the rate at which existing cases die. 1 The "Global Campaign against Epilepsy demonstration project" was launched in China in 2000. Over more than a decade, this project was effective and made a difference to epilepsy care in China, especially in rural areas. 15 As well as benefits brought by economic growth, swift urbanization and healthcare improvement, some well-documented risk factors, such as consanguineous marriage, febrile seizures, prenatal and perinatal central nervous system deficits and infections, may have decreased in China. [19] [20] [21] These could account for a decrease in the incidence of epilepsy.
As shown in the incidence-prevalence-mortality model in Figure 3 , irrespective of mortality, life-time prevalence should increase with age, or remain unchanged if the incidence is zero ( Figure 3A ). When the death rate is higher than the incidence rate, the prevalence rate decreases ( Figure 3B ). The discrepancy in prevalence rates at different time points in the same areas highlights the importance of taking premature mortality into account. Generally, epilepsy mortality rates are considered to be 1.3 to 9.3 fold higher than in the general population and this could be even higher in poorsettings. [22] [23] [24] Anecdotal evidence from high-income countries suggests that a potential reason for few older people with a life history of epilepsy being seen in epilepsy clinics is premature death, 5 although cerebrovascular disease and trauma are potential risk factors in older adults. 25, 26 It has been suggested that a higher mortality rate in low-and middle-income countries may explain the discrepancy between high incidence and relatively low prevalence. 5, 27 A small study in rural Laos, with an estimated prevalence of 7.7‰, found that almost one in nine people with epilepsy died within a short period. 28 In China, a cohort study reported that around one fifth died over a 12 years period. 29 Long-term follow-up of cohorts found premature mortality was higher in people with epilepsy than in the general population and much higher in young people. 30, 31 Sudden unexpected death in epilepsy, an important cause of premature mortality in people with epilepsy, was estimated to have higher incidence in China than in high-income countries. 32 We hypothesize that the decreasing life-time prevalence we found is attributed to a combination of a lower incidence rate and higher premature mortality. Effective ways should be implemented to reduce premature mortality.
Our study has limitations. Firstly, although highly specific and sensitive screening tools and strict diagnostic procedures were used, epilepsy is a condition with a long history of stigma and discrimination influencing individuals' attitude toward disclosure of a diagnosis, so epilepsy prevalence might have been underestimated.
Using an identical survey protocol, in the same general survey areas, however, and with no evidence of increasing concealment, we found a difference in the two surveys.
Secondly, compared to the 2000-2002 survey, the sample size of the 2010-2013 survey was smaller; it was, however, large enough to obtain an adequate crosssectional prevalence based on the sample size calculation. Thirdly, data in the surveys may not fully reflect the overall Chinese situation. Nevertheless, our target areas represented rural and urban areas of China. Fourthly, there is incomplete overlap of the surveyed population at the two time points. The target survey populations are, however, in adjacent areas receiving the same level of care and having subjects with similar social and demographic changes over the time period. Lastly, the lack of datasets of concurrent active prevalence, incidence, mortality and treatment gap hinder us from analyzing the change in the full epilepsy burden in China.
Our findings differ from the recognized upward trend in life-time epilepsy prevalence. Epilepsy seems to be decreasing in China, but we suspect it may be related to decreased incidence and increased premature mortality. High-quality, largesample, multi-center epidemiological surveys collecting concurrent data on incidence, prevalence, mortality in low-and middle-income countries are warranted to confirm a change in the epilepsy burden.
